Search results
Results from the WOW.Com Content Network
U.S. FDA Approves ELIQUIS ® (apixaban) to Reduce the Risk of Stroke and Systemic Embolism in Patients with Nonvalvular Atrial Fibrillation ELIQUIS Demonstrated Superior Risk Reductions Versus ...
Online patient education is gaining popularity as home Internet access becomes more common and medical practices increasingly utilize digital technologies. [2] [3] Patients either view online patient education programs and materials in a medical office or from their homes or other remote locations with Internet access. Content may include ...
Rivaroxaban (Xarelto) was the first approved FXa inhibitor to become commercially available in Europe and Canada in 2008. [1] The second one was apixaban (Eliquis), approved in Europe in 2011 [2] and in the United States in 2012. [3] The third one edoxaban (Lixiana, Savaysa) was approved in Japan in 2011 and in Europe and the US in 2015. [4]
Apixaban is recommended by the National Institute for Health and Clinical Excellence for the prevention of stroke and systemic embolism in people with non-valvular atrial fibrillation and at least one of the following risk factors: prior stroke or transient ischemic attack, age 75 years or older, diabetes, or symptomatic heart failure.
A Radiographer explains an x-ray to a coal miner participating in screening. Patient education can include explaining the results of diagnostic tests. Patient education is a planned interactive learning process designed to support and enable expert patients [1] to manage their life with a disease and/or optimise their health and well-being. [2] [3]
An anticoagulant, commonly known as a blood thinner, is a chemical substance that prevents or reduces the coagulation of blood, prolonging the clotting time. [1] Some occur naturally in blood-eating animals, such as leeches and mosquitoes, which help keep the bite area unclotted long enough for the animal to obtain blood.
The New Revised Standard Version (NRSV) is a translation of the Bible in contemporary English.It was first published in 1989 by the National Council of Churches, [5] the NRSV was created by an ecumenical committee of scholars "comprising about thirty members".
Warfarin is indicated for the prophylaxis and treatment of venous thrombosis and its extension, pulmonary embolism; [9] prophylaxis and treatment of thromboembolic complications associated with atrial fibrillation and/or cardiac valve replacement; [9] and reduction in the risk of death, recurrent myocardial infarction, and thromboembolic events such as stroke or systemic embolization after ...